AbbVie (ABBV) confirms it is to acquire Apogee Therapeutics (APGE)
- Under the terms of the transaction, AbbVie will acquire all outstanding shares of Apogee for USD 135.11/shr in cash.
- The transaction values Apogee at a total equity value of approximately USD 10.9bln.
- The boards of directors of both companies have unanimously approved the transaction.
- This transaction is expected to close in the third quarter of 2026, subject to customary closing conditions, including Apogee shareholder approval and receipt of regulatory approvals.
#ABBVIE INC#ABBV.US#EQUITIES#EU SESSION#US SESSION#BIOTECHNOLOGY#BIOTECHNOLOGY (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#S&P 500 INDEX#ABBVIE INC#ABBV#US EQUITIES